INFI News and Press, Infinity Pharmaceuticals Inc. From 07/28/21

Gainers: Bit Digital (BTBT) +51%.Infinity Pharmaceuticals (INFI) +46%.NanoVibronix (NAOV) +40%.Tilray (TLRY) +26%.Flora Growth Corp. (FLGC) +25%.Youdao (DAO) +24%.Grove (GRVI) +22%.Zhangmen Education (ZME) +23%.First High-School Education (FHS) +22%.Canaan (CAN) +21%.Losers: Hoegh LNG Partner...

naphtalina/iStock via Getty Images The shares of Infinity Pharmaceuticals ([[INFI]] +46.7%) have surged in morning hours after losing nearly a third on Tuesday in apparent reaction to updated data from two mid-stage studies for the company’s oral immuno-oncology candidate, eganeli...

Gainers: Infinity Pharmaceuticals (INFI) +62%, Grove (GRVI) +26%, Shineco (TYHT) +24%, Tilray TLRY +22%, NeuroMetrix (NURO) +19%.Losers: Dyadic (DYAI) -14%, EyeGate Pharmaceuticals (EYEG) -13%, NanoViricides (NNVC) -13%, Myovant Sciences MYOV&...

Bit Digital (BTBT) +39%.Infinity Pharmaceuticals (INFI) +42%.Support.com (SPRT) +36%.Grove (GRVI) +25%.Taoping (TAOP) +24% on proposing to acquire 51% stake in Zhenjiang TaopingThe9 (NCTY) +13%.China Natural Resources (CHNR) +14%.ATA Creativity (AACG) +14%.TAL Education ( TAL) ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We’re halfway through the week and still going strong with a look at the biggest pre-market stock movers for Wednesday! Source: Eric Urquhart/Shutterstock.com But don’t get too ...

Gainers: Intrusion (INTZ) +65%.MOGU (MOGU) +40%.Oragenics (OGEN) +32%.BiondVax Pharmaceuticals (BVXV) +29%.Sintx Technologies (SINT) +23%.Dyadic International (DYAI) +21%.EyeGate Pharmaceuticals (EYEG) +19%.U.S. Physical Therapy (USPH) +18%.ObsEva SA (OBSV) +16%.Orbsat (OSAT) +15%.Losers: IRS...

IRSA Propiedades Comerciales (IRCP) -69%.Infinity Pharmaceuticals (INFI) -23% on Q2 earnings release and updates data from bladder and breast cancer trials.TRxADE HEALTH (MEDS) -20% on Q2 earnings release.Bit Digital (BTBT) -17%.Flora Growth (FLGC) -15% to f...

luismmolina/E+ via Getty Images Infinity Pharmaceuticals (INFI) issued data updates from two mid-stage trials for eganelisib, the company’s oral immuno-oncology candidate. 49 patients were enrolled in the MARIO-275 study that was designed to evaluate it as a combination therapy wi...

Infinity Pharmaceuticals (INFI): Q2 GAAP EPS of -$0.13 beats by $0.01.Royalty revenue of $0.51M (+41.7% Y/Y) beats by $0.27MAt June 30, 2021, Infinity had total cash, cash equivalents and available-for-sale securities of $97.3M, compared to $106.8M at March 31, 2021.Financial Outloo...

- New clinical data from MARIO-275 and MARIO-3 suggest that the addition of eganelisib to standard of care regimens provides patient benefit - - Increases seen in overall survival in 2L urothelial cancer (UC) and in progression free survival in 1L triple negative breast cancer...